EGFR and adenocarcinoma: Our results are also consistent with the findings of other studies [46,47,48,49,50,51,52] demonstrating the efficacy of erlotinib in a diverse NSCLC patient population regardless of EGFR status, NSCLC type (adenocarcinoma or squamous-cell carcinoma), TMB, and chemotherapy history.